Gene therapy as an alternative to liver transplantation

Liver Transplantation

Volumn 8, Issue 12, 2002, Pages 1089-1108

  Kren, Betsy T ^a   Chowdhury, Namita Roy ^b   Chowdhury, Jayanta Roy ^b   Steer, Clifford J ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; ASIALOFETUIN; ASIALOGLYCOPROTEIN RECEPTOR; ASIALOOROSOMUCOID; BLOOD CLOTTING FACTOR 9; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DNA; ESTER DERIVATIVE; GALACTOSE; GUANINE NUCLEOTIDE BINDING PROTEIN; HELICASE; HYDROXYUREA; INFLUENZA VIRUS HEMAGGLUTININ; LIPOFECTAMINE; LUCIFERASE; NAKED DNA; NUCLEIC ACID; OLIGONUCLEOTIDE; PHOSPHOROTHIOIC ACID DERIVATIVE; POLIOMYELITIS VACCINE; POLYETHYLENEIMINE; POLYLYSINE; RIBONUCLEASE; RIBOZYME; SUPEROXIDE DISMUTASE; TRANSPOSASE; TUMOR VACCINE; UNINDEXED DRUG; VIRUS PROTEIN; VIRUS RNA; VIRUS VECTOR;

ACUTE DISEASE; CHRONIC LIVER DISEASE; DNA REPAIR; DOSE RESPONSE; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; FEMALE; GENE REPLACEMENT THERAPY; GENE TARGETING; GENETIC DISORDER; GENETIC PROCEDURES; HEPATITIS; HUMAN; INBORN ERROR OF METABOLISM; LIVER FAILURE; LIVER INJURY; LIVER TRANSPLANTATION; LOW DRUG DOSE; NEWBORN; NONHUMAN; NONVIRAL GENE THERAPY; NUCLEIC ACID PROBE; ORGAN DONOR; PRIORITY JOURNAL; REVIEW; TRANSPOSON; VIRAL GENE THERAPY; ANIMAL; COMPARATIVE STUDY; DISEASE MODEL; GENE THERAPY; GENE VECTOR; METHODOLOGY;

ANIMALS; DISEASE MODELS, ANIMAL; DNA REPAIR; DNA TRANSPOSABLE ELEMENTS; GENE THERAPY; GENETIC VECTORS; HUMANS; LIVER FAILURE; LIVER TRANSPLANTATION;

EID: 0036915912     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1053/jlts.2002.36844     Document Type: Article

References (171)

1. Kay MA, Glorioso JC, Naldini L. Viral vectors for gene therapy: The art of turning infectious agents into vehicles of therapeutics. Nat Med 2001;7:33-40.
2. Klimatcheva E, Rosenblatt JD, Planelles V. Lentiviral vectors and gene therapy. Front Biosci 1999;4:D481-D496.
3. Smith-Arica JR, Bartlett JS. Gene therapy: Recombinant adeno-associated virus vectors. Curr Cardiol Rep 2001;3:43-49.
4. Ashwell G, Morell AG. The role of surface carbohydrates in the hepatic recognition and transport of circulating glycoproteins. Adv Enzymol 1974;41:99-128.
5. Chowdhury JR, Grossman M, Gupta S, Chowdhury NR, Baker JR Jr, Wilson JM. Long term improvement of hypercholesterolemia after ex vivo gene therapy in LDL-receptor deficient rabbits. Science 1991;254:1802-1805.
6. Lehmann TG, Wheeler MD, Schwabe RF, Connor HD, Schoonhoven R, Bunzendahl H, et al. Gene delivery of Cu/Zn-superoxide dismutase improves graft function after transplantation of fatty livers in the rat. Hepatology 2000;32:1255-1264.
7. Wood KJ. Gene therapy and allotransplantation. Curr Opin Immunol 1997;9:662-668.
8. Wood KJ. Potential of gene transfer in transplantation. Transplant Proc 1999;31:1814-1816.
9. Müller K, Heller H, Doerfler W. Foreign DNA integration. Genome-wide perturbations of methylation and transcription in the recipient genomes. J Biol Chem 2001;276:14271-14278.
10. Baylin SB, Esteller M, Rountree MR, Bachman KE, Schuebel K, Herman, JG. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet 2001;10:687-692.
11. Santini V, Kantarjian HM, Issa, JP. Changes in DNA methylation in neoplasia: Pathophysiology and therapeutic implications. Ann Intern Med 2001;134:573-586.
12. Tada K, Chowdhury NR, Neufeld D, Bosma PJ, Heard M, Prasad VR, et al. Long-term reduction of serum bilirubin levels in Gunn rats by retroviral gene transfer in vivo. Liver Transplant Surg 1998;4:78-88.
13. Park F, Ohashi K, Chiu W, Naldini L, Kay MA. Efficient lentiviral transduction of liver requires cell cycling in vivo. Nature Genet 2000;24:49-52.
14. Ohashi K, Park F, Kay MA. Role of hepatocyte direct hyperplasia in lentivirus-mediated liver transduction in vivo. Hum Gene Ther 2002;13:653-663.
15. Park F, Ohashi K, Kay MA. Therapeutic levels of human factor VIII and IX using HIV-1-based lentiviral vectors in mouse liver. Blood 2000;96:1173-1176.
16. Jaffe HA, Danel C, Longenecker G, Metzger M, Setoguchi Y, Rosenfeld MA, et al. Adenovirus-mediated in vivo gene transfer and expression in normal rat liver. Nat Genet 1992;1:372-378.
17. Takahashi M, Ilan Y, Chowdhury NR, Guida J, Horwitz M, Chowdhury JR. Long term correction of bilirubin-UDP-glucuronosyltransferase deficiency in Gunn rats by administration of a recombinant adenovirus during the neonatal period. J Biol Chem 1996;271:26536-26542.
18. Ilan Y, Attavar P, Takahashi M, Davidson A, Horwitz MS, Guida J, et al. Induction of central tolerance by intrathymic inoculation of adenoviral antigens into the host thymus permits long-term gene therapy in Gunn rats. J Clin Invest 1996;98:2640-2647.
19. Ilan Y, Sauter B, Chowdhury NR, Reddy BV, Thummala NR, Droguett G, et al. Oral tolerization to adenoviral proteins permits repeated adenovirus-mediated gene therapy in rats with preexisting immunity to adenovirus. Hepatology 1998;27:1368-1376.
20. Ilan Y, Jona VK, Sengupta K, Davidson A, Horwitz MS, Chowdhury NR, et al. Transient immunosuppression with FK506 permits long-term expression of therapeutic genes introduced into the liver using recombinant adenoviruses in the rat. Hepatology 1997;26:949-956.
21. Parks RJ, Graham FL. A helper-dependent system for adenovirus vector production helps define lower limit for efficient DNA packaging. J Virol 1997;71:3293-3298.
22. Kafri T, Morgan D, Krahl T, Sarvetnick N, Sherman L, Verma I. Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression: implications for gene therapy. Proc Natl Acad Sci U S A 1998;95:11377-11382.
23. Ilan Y, Droguett G, Chowdhury NR, Li Y, Sengupta K, Thummala NR, et al. Insertion of the adenoviral E3 region into a recombinant viral vector prevents antiviral humoral and cellular immune responses and permits long-term gene expression. Proc Natl Acad Sci U S A 1997;94:2587-2592.
24. Thummala NR, Ghosh SS, Lee SW, Caton M, Davidson A, Reddy B, et al. A non-immunogenic adenoviral vector, coexpressing CTLA4Ig and bilurubin-UDP-glucuronosyltransferase (UGT1A1) permits long-term, repeatable transgene expression in the Gunn rat model of Crigler-Najjar syndrome type 1. Hepatology 2001;34:A357.
25. Bergelson JM, Cunningham JA, Kurt-Jones EA, Krithivas A, Hong JS, Horwitz MS, et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997;275:1320-1323.
26. Cohen CJ, Shieh JT, Pickles RJ, Okegawa T, Hsieh JT, Bergelson JM. The coxsackievirus and adenovirus receptor is a transmembrane component of the tight junction. Proc Natl Acad Sci U S A 2001;98:15191-15196.
27. Raper SE, Yudkoff M, Chirmule N, Gao GP, Nunes F, Haskal ZJ, et al. A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency. Hum Gene Ther 2002; 13:163-175.
28. Sauter BV, Parashar B, Chowdhury NR, Kadakol A, Ilan Y, Singh H, et al. A replication-deficient rSV40 mediates liver-directed gene transfer and a long-term amelioration of jaundice in Gunn rats. Gastroenterology 2000; 119:1348-1357.
29. Samulski RJ, Zhu X, Xiao X, Brook JD, Housman DE, Epstein N, et al. Targeted integration of adeno-associated virus (AAV) into human chromosome 19. EMBO J 1991; 10:3941-3950.
30. Walz C, Schlehofer JR, Flentje M, Rudat V, zur Hausen H. Adeno-associated virus sensitizes HeLa cell tumors to gamma rays. J Virol 1992;66:5651-5657.
31. Song S, Laipis PJ, Berns KI, Flotte TR. Effect of DNA-dependent protein kinase on the molecular fate of the rAAV2 genome in skeletal muscle. Proc Natl Acad Sci U S A 2001;98:4084-4088.
32. Wang L, Nichols TC, Read MS, Bellinger DA, Verma IM. Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver. Mol Ther 2000;1:154-158.
33. Fong Y, Federoff HJ, Brownlee M, Blumberg D, Blumgart LH, Brennan ME. Rapid and efficient gene transfer in human hepatocytes by herpes viral vectors. Hepatology 1995;22:723-729.
34. Hoffmann C, Sandig V, Jennings G. Efficient gene transfer into human hepatocytes by baculovirus vectors. Proc Natl Acad Sci U S A 1995;92:10099-10103.
35. Einfeld, DA, Schroeder R, Roelvink PW, Lizonova A, King CR, Kovesdi I, et al. Reducing the native tropism of adenovirus vectors requires removal of both CAR and integrin interactions. J Virol 2001;75:11284-11291.
36. Kay MA, Manno CS, Ragni MV, Larson PJ, Couto LB, McClelland A, et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet 2000;24:257-261.
37. Strayer DS, Branco F, Zern MA, Yam P, Calarota SA, Nichols CN, et al. Durability of transgene expression and vector integration: Recombinant SV40-derived gene therapy vectors. Mol Ther 2002;6:227-237.
38. Zhang L, Sankar U, Lampe DJ, Robertson HM, Graham FL. The Himar1 mariner transposase cloned in a recombinant adenovirus vector is functional in mammalian cells. Nucleic Acids Res 1998;26:3687-3693.
39. Ivics Z, Hackett PB, Plasterk RH, Izsvák Z. Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells. Cell 1997;91:501-510.
40. van Luenen HG, Colloms SD, Plasterk RH. The mechanism of transposition of Tc3 in C. elegans. Cell 1994;79:293-301.
41. Izsvák Z, Ivics Z, Plasterk RH. Sleeping Beauty, a wide host-range transposon vector for genetic transformation in vertebrates. J Mol Biol 2000;302:93-102.
42. Luo G, Ivics Z, Izsvak Z, Bradley A. Chromosomal transposition of a Tc1/mariner-like element in mouse embryonic stem cells. Proc Natl Acad Sci U S A 1998;95:10769-10773.
43. Yant SR, Meuse L, Chiu. W, Ivics Z, Izsvak Z, Kay MA. Somatic integration and long-term transgene expression in normal and haemophilic mice using a DNA transposon system. Nat Genet 2000;25:35-41.
44. Fischer SE, Wienholds E, Plasterk RH. Regulated transposition of a fish transposon in the mouse germ line. Proc Natl Acad Sci U S A 2001;98:6759-6764.
45. Krieg AM. Direct immunologic activities of CpG DNA and implications for gene therapy. J Gene Med 1999;1:56-63.
46. Kruger K, Grabowski PJ, Zaug AJ, Sands J, Gottschling DE, Cech TR. Self-splicing RNA: Autoexcision and autocyclization of the ribosomal RNA intervening sequence of Tetrahymena. Cell 1982;31:147-157.
47. Symons RH. Self-cleavage of RNA in the replication of small pathogens of plants and animals. Trends Biochem Sci 1989;14:445-450.
48. Welch PJ, Barber JR, Wong-Staal F. Expression of ribozymes in gene transfer systems to modulate target RNA levels. Curr Opin Biotechnol 1998;9:486-496.
49. Fedor MJ. Structure and function of the hairpin ribozyme. J Mol Biol 2000;297:269-291.
50. Lieber A, Kay MA. Adenovirus-mediated expression of ribozymes in mice. J Virol 1996;70:3153-3158.
51. Lieber A, He CY, Polyak SJ, Gretch DR, Barr D, Kay MA. Elimination of hepatitis C virus RNA in infected human hepatocytes by adenovirus-mediated expression of ribozymes. J Virol 1996;70:8782-8791.
52. Welch PJ, Tritz R, Yei S, Leavitt M, Yu M, Barber J. A potential therapeutic application of hairpin ribozymes: In vitro and in vivo studies of gene therapy for hepatitis C virus infection. Gene Ther 1996;3:994-1001.
53. Sakamoto N, Wu CH, Wu GY. Intracellular cleavage of hepatitis C virus RNA and inhibition of viral protein translation by hammerhead ribozymes. J Clin Invest 1996;98:2720-2728.
54. Welch PJ, Yei S, Barber JR. Ribozyme gene therapy for hepatitis C virus infection. Clin Diagn Virol 1998; 10:163-171.
55. Welch PJ, Tritz R, Yei S, Barber J, Yu M. Intracellular application of hairpin ribozyme genes against hepatitis B virus. Gene Ther 1997;4:736-743.
56. Weinberg M, Passman M, Kew M, Arbuthnot P. Hammerhead ribozyme-mediated inhibition of hepatitis B virus X gene expression in cultured cells. J Hepatol 2000;33:142-151.
57. Feng Y, Kong YY, Wang Y, Qi GR. Inhibition of hepatitis B virus by hammerhead ribozyme targeted to the poly(A) signal sequence in cultured cells. Biol Chem 2001;382:655-660.
58. Enjoji M, Wang F, Nakamuta M, Chan L, Teng BB. Hammerhead ribozyme as a therapeutic agent for hyperlipidemia: Production of truncated apolipoprotein B and hypolipidemic effects in a dyslipidemia murine model. Hum Gene Ther 2000;11:2415-2430.
59. Pavco PA, Bouhana KS, Gallegos AM, Agrawal A, Blanchard KS, Grimm S, et al. Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors. Clin Cancer Res 2000;6:2094-2103.
60. Oketani M, Asahina Y, Wu CH, Wu GY. Inhibition of hepatitis C virus-directed gene expression by a DNA ribonuclease. J Hepatol 1999;31:628-634.
61. Asahina Y, Ito Y, Wu CH, Wu GY. DNA ribonucleases that are active against intracellular hepatitis B viral RNA targets. Hepatology 1998;28:547-554.
62. Nakazono K, Ito Y, Wu CH, Wu GY. Inhibition of hepatitis B virus replication by targeted pretreatment of complexed antisense DNA in vitro. Hepatology 1996;23:1297-1303.
63. Robaczewska M, Guerret S, Remy JS, Chemin I, Offensperger WB, Chevallier M, et al. Inhibition of hepadnaviral replication by polyethylenimine-based intravenous delivery of antisense phosphodiester oligodeoxynucleotides to the liver. Gene Ther 2001;8:874-881.
64. Kang MA, Kim KY, Seol JY, Kim KC, Nam MJ. The growth inhibition of hepatoma by gene transfer of antisense vascular endothelial growth factor. J Gene Med 2000;2:289-296.
65. Zhang H, Cook J, Nickel J, Yu R, Stecker K, Myers K, et al. Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis. Nat Biotechnol 2000;18:862-867.
66. Butler M, McKay RA, Popoff IJ, Gaarde WA, Witchell D, Murray SF, et al. Specific Inhibition of PTEN expression reverses hyperglycemia in diabetic mice. Diabetes 2002;51:1028-1034.
67. Maggard M, Meng L, Ke B, Allen R, Devgan L, Imagawa DK Antisense TGF-β2 immunotherapy for hepatocellular carcinoma: treatment in a rat tumor model. Ann Surg Oncol 2001;8:32-37.
68. Brand RM, Hannah TL, Norris J, Iversen PL. Transdermal delivery of antisense oligonucleotides can induce changes in gene expression in vivo. Antisense Nucleic Acid Drug Dev 2001;11:1-6.
69. Lambert G, Fattal E, Couvreur P, Brand RM, Hannah TL, Norris J, et al. Nanoparticulate systems for the delivery of antisense oligonucleotides. Adv Drug Deliv Rev 2001;47:99-112.
70. Ponnappa BC, Dey I, Tu GC, Zhou F, Aini M, Cao QN, et al. In vivo delivery of antisense oligonucleotides in pH-sensitive liposomes inhibits lipopolysaccharide-induced production of tumor necrosis factor-alpha in rats. J Pharmacol Exp Ther 2001;297:1129-1136.
71. Arora V, Knapp DC, Reddy MT, Weller DD, Iversen PL. Bioavailability and efficacy of antisense morpholino oligomers targeted to c-myc and cytochrome P-450 3A2 following oral administration in rats. J Pharm Sci 2002;91:1009-1018.
72. Biessen EA, Sliedregt-Bol K, 'T Hoen PA, Prince P, Van der Bilt E, Valentijn AR, et al. Design of a targeted peptide nucleic acid prodrug to inhibit hepatic human microsomal triglyceride transfer protein expression in hepatocytes. Bioconjug Chem 2002;13:295-302.
73. Kawabata K, Takakura Y, Hashida M. The fate of plasmid DNA after intravenous injection in mice: Involvement of scavenger receptors in its hepatic uptake. Pharm. Res 1995; 12:825-830.
74. Yoshida M, Mahato RI, Kawabata K, Takakura Y, Hashida M. Disposition characteristics of plasmid DNA in the single-pass rat liver perfusion system. Pharm. Res 1996; 13:599-603.
75. Budker V, Budker T, Zhang G, Subbotin V, Loomis A, Wolff JA. Hypothesis: Naked plasmid DNA is taken up by cells in vivo by a receptor-mediated process. J Gene Med 2000;2:76-88.
76. Hickman MA, Malone RW, Lehmann-Bruinsma K, Sih TR, Knoell D, Szoka FC, et al. Gene expression following direct injection of DNA into liver. Hum Gene Ther 1994;5:1477-1483.
77. Yang NS, Burkholder J, Roberts B, Martinell B, McCabe D. In vivo and in vitro gene transfer to mammalian somatic cells by particle bombardment. Proc Nad Acad Sci U S A 1990;87:9568-9572.
78. Yoshida S, Kashiwamura SI, Hosoya Y, Luo E, Matsuoka H, Ishii A, et al. Direct immunization of malaria DNA vaccine into the liver by gene gun protects against lethal challenge of Plasmodium berghei sporozoite. Biochem Biophys Res Commun 2000;271:107-115.
79. Budker V, Zhang G, Knechtle S, Wolff JA. Naked DNA delivered intraportally expresses efficiently in hepatocytes. Gene Ther 1996;3:593-598.
80. Zhang G, Vargo D, Budker V, Armstrong N, Knechtle S, Wolff JA. Expression of naked plasmid DNA injected into the afferent and efferent vessels of rodent and dog livers. Hum Gene Ther 1997;8:1763-1772.
81. Zhang G, Budker V, Wolff JA. High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA. Hum Gene Ther 1999;10:1735-1737.
82. Liu F, Song Y, Liu D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther 1999;6:1258-1266.
83. Yang J, Chen S, Huang L, Michalopoulos GK, Liu Y. Sustained expression of naked plasmid DNA encoding hepatocyte growth factor in mice promotes liver and overall body growth. Hepatology 2001;33:848-859.
84. Chang J, Sigal LJ, Lerro A, Taylor J. Replication of the human hepatitis delta virus genome is initiated in mouse hepatocytes following intravenous injection of naked DNA or RNA sequences. J Virol 2001;75:3469-3473.
85. Felgner PL, Barenholz Y, Behr JP, Cheng SH, Cullis P, Huang L, et al. Nomenclature for synthetic gene delivery systems. Hum Gene Ther 1997;8:511-512.
86. Findeis MA, Wu CH, Wu GY. Ligand-based carrier systems for delivery of DNA to hepatocytes. Meth Enzymol 1994;247:341-351.
87. Boussif O, Lezoualc'h F, Zanta MA, Mergny MD, Scherman D, Demeneix B, et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: Polyethylenimine. Proc Natl Acad Sci U S A 1995;92:7297-7301.
88. Goldman CK, Soroceanu L, Smith N, Gillespie GY, Shaw W, Burgess S, et al. In vitro and in vivo gene delivery mediated by a synthetic polycationic amino polymer. Nat Biotechnol 1997;15:462-466.
89. Erbacher P, Zou S, Bettinger T, Steffan AM, Remy JS. Chitosan-based vector/DNA complexes for gene delivery: Biophysical characteristics and transfection ability. Pharm. Res 1998;15:1332-1339.
90. Remy JS, Kichler A, Mordvinov V, Schuber F, Behr JP. Targeted gene transfer into hepatoma cells with lipopolyamine-condensed DNA particles presenting galactose ligands: A stage toward artificial viruses. Proc Natl Acad Sci U S A 1995;92:1744-1748.
91. Murphy JE, Uno T, Hamer JD, Cohen FE, Dwarki V, Zuckermann RN. A combinatorial approach to the discovery of efficient cationic peptoid reagents for gene delivery. Proc Natl Acad Sci U S A 1998;95:1517-1522.
92. Nicolau C, Le Pape A, Soriano P, Fargette F, Juhel MF. In vivo expression of rat insulin after intravenous administration of the liposome-entrapped gene for rat insulin I. Proc Natl Acad Sci U S A 1983;80:1068-1072.
93. Lee RJ, Huang L. Folate-targeted, anionic liposome-entrapped polylysine-condensed DNA for tumor cell-specific gene transfer. J Biol Chem 1996;271:8481-8487.
94. Bandyopadhyay P, Kren BT, Ma X, Steer CJ. Enhanced gene transfer into HuH-7 cells and primary rat hepatocytes using targeted liposomes and polyethylenimine. BioTechniques 1998;25:282-292.
95. Yamazaki Y, Nango M, Matsuura M, Hasegawa Y, Hasegawa M, Oku N. Polycation liposomes, a novel nonviral gene transfer system, constructed from cetylated polyethylenimine. Gene Ther 2000;7:1148-1155.
96. Kaneda Y, Saeki Y, Morishita R, Crespo A, Alino SF. Gene therapy using HVJ-liposomes: The best of both worlds? Mol Med Today 1999;5:298-303.
97. Uehara T, Honda K, Hatano E, Terao R, Iimuro Y, Yamamoto N, et al. Gene transfer to the rat biliary tract with the HVJ-cationic liposome method. J Hepatol 1999;30:836-842.
98. Hirano T, Kaneko S, Kaneda Y, Saito I, Tamaoki T, Furuyama J, et al. HVJ-liposome-mediated transfection of HSVtk gene driven by AFP promoter inhibits hepatic tumor growth of hepatocellular carcinoma in SCID mice. Gene Ther 2001;8:80-83.
99. Zabner J, Fasbender AJ, Moninger T, Poellinger KA, Welsh MJ. Cellular and molecular barriers to gene transfer by a cationic lipid. J Biol Chem 1995;270:18997-19007.
100. Subramanian A, Ranganathan P, Diamond SL. Nuclear targeting peptide scaffolds for lipofection of nondividing mammalian cells. Nat Biotechnol 1999;17:873-877.
101. Fischer D, Bieber T, Li Y, Elsasser HP, Kissel T. A novel non-viral vector for DNA delivery based on low molecular weight, branched polyethylenimine: Effect of molecular weight on transfection efficiency and cytotoxicity. Pharm Res 1999; 16:1273-1279.
102. Friend DS, Papahadjopoulos D, Debs RJ. Endocytosis and intracellular processing accompanying transfection mediated by cationic liposomes. Biochim Biophys Acta 1996;1278:41-50.
103. Labat-Moleur F, Steffan AM, Brisson C, Perron H, Feugeas O, Furstenberger P, et al. An electron microscopy study into the mechanism of gene transfer with lipopolyamines. Gene Ther 1996;3:1010-1017.
104. Lappalainen K, Jaaskelainen I, Syrjanen K, Urtti A, Syrjanen S. Comparison of cell proliferation and toxicity assays using two cationic liposomes. Pharm Res 1994;11:1127-1131.
105. Li S, Rizzo MA, Bhattacharya S, Huang L. Characterization of cationic lipid-protamine-DNA (LPD) complexes for intravenous gene delivery. Gene Ther 1998;5:930-937.
106. Ogris M, Brunner S, Schuller S, Kircheis R, Wagner E. PEGy-lated DNA/transferrin-PEI complexes: Reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery. Gene Ther 1999;6:595-605.
107. Hara T, Tan Y, Huang L. In vivo gene delivery to the liver using reconstituted chylomicron remnants as a novel nonviral vector. Proc Natl Acad Sci U S A 1997;94:14547-14552.
108. Martinez-Fong D, Mullersman JE, Purchio AF, Armendariz-Borunda J, Martinez-Hernandez A. Nonenzymatic glycosylation of poly-L-lysine: A new tool for targeted gene delivery. Hepatology 1994;20:1602-1608.
109. Dasi F, Benet M, Crespo J, Crespo A, Alino SF. Asialofetuin liposome-mediated human alpha1-antitrypsin gene transfer in vivo results in stationary long-term gene expression. J Mol Med 2001;79:205-212.
110. Perales JC, Grossmann GA, Molas M, Liu G, Ferkol T, Harpst J, et al. Biochemical and functional characterization of DNA complexes capable of targeting genes to hepatocytes via the asialoglycoprotein receptor. J Biol Chem 1997;272:7398-7407.
111. Bandyopadhyay P, Ma X, Linehan-Stieers C, Kren BT, Steer CJ. Nucleotide exchange in genomic DNA of rat hepatocytes using RNA/DNA oligonucleotides. Targeted delivery of liposomes and polyethyleneimine to the asialoglycoprotein receptor. J Biol Chem 1999;274:10163-10172.
112. Spanjer HH, Scherphof GL. Targeting of lactosylceramide-containing liposomes to hepatocytes in vivo. Biochim Biophys Acta 1983;734:40-47.
113. Wu GY, Wu CH. Receptor-mediated gene delivery and expression in vivo. J Biol Chem 1988;263:14621-14624.
114. Chowdhury NR, Wu CH, Wu GY, Yerneni PC, Bommineni VR, Chowdhury JR. Fate of DNA targeted to the liver by asialoglycoprotein receptor-mediated endocytosis in vivo. Prolonged persistence in cytoplasmic vesicles after partial hepatectomy. J Biol Chem 1993;268:11265-11271.
115. Bettinger T, Remy JS, Erbacher P. Size reduction of galactosylated PEI/DNA complexes improves lectin-mediated gene transfer into hepatocytes. Bioconjug Chem 1999;10:558-561.
116. Coonrod A, Li FQ Horwitz M. On the mechanism of DNA transfection: Efficient gene transfer without viruses. Gene Ther 1997;4:1313-1321.
117. Seol JG, Heo DS, Kim HK, Yoon JH, Choi BI, Lee HS, et al. Selective gene expression in hepatic tumor with trans-arterial delivery of DNA/liposome/transferrin complex. In Vivo 2000;14:513-517.
118. Mohr L, Yoon SK, Eastman SJ, Chu Q, Scheule RK, Scaglioni PP, et al. Cationic liposome-mediated gene delivery to the liver and to hepatocellular carcinomas in mice. Hum Gene Ther 2001;12:799-809.
119. Kircheis R, Kichler A, Wallner G, Kursa M, Ogris M, Felzmann T, et al. Coupling of cell-binding ligands to polyethylenimine for targeted gene delivery. Gene Ther 1997;4:409-418.
120. Mahato RI, Kawabata K, Takakura Y, Hashida M. In vivo disposition characteristics of plasmid DNA complexed with cationic liposomes. J Drug Target 1995;3:149-157.
121. Weis WI, Cusack SC, Brown JH, Daniels RS, Skehel JJ, Wiley DC. The structure of a membrane fusion mutant of the influenza virus haemagglutinin. EMBO J 1990;9:17-24.
122. Steinhauer DA, Wharton SA, Skehel JJ, Wiley DC. Studies of the membrane fusion activities of fusion peptide mutants of influenza virus hemagglutinin. J Virol 1995;69:6643-6651.
123. Godbey WT, Wu KK, Hirasaki GJ, Mikos AG. Improved packing of poly(ethylenimine)/DNA complexes increases transfection efficiency. Gene Ther 1999;6:1380-1388.
124. Lecocq M, Wattiaux-De Coninck S, Laurent N, Wattiaux R, Jadot M. Uptake and intracellular fate of polyethylenimine in vivo. Biochem Biophys Res Commun 2000;278:414-418.
125. Oh Y-K, Kim J-P, Yoon H, Kim JM, Kim C-K. Prolonged organ retention and safety of plasmid DNA administered in polyethylenimine complexes. Gene Ther 2001;8:1587-1592.
126. Pollard H, Remy JS, Loussouarn G, Demolombe S, Behr JP, Escande D. Polyethylenimine but not cationic lipids promotes transgene delivery to the nucleus in mammalian cells. J Biol Chem 1998;273:7507-7511.
127. Vacik J, Dean BS, Zimmer WE, Dean DA. Cell-specific nuclear import of plasmid DNA. Gene Ther 1999;6:1006-1014.
128. Zanta MA, Belguise-Valladier P, Behr JP. Gene delivery: A single nuclear localization signal peptide is sufficient to carry DNA to the cell nucleus. Proc Natl Acad Sci U S A 1999;96:91-96.
129. Aronsohn AI, Hughes JA, Crespo A, Alino SF. Nuclear localization signal peptides enhance cationic liposome-mediated gene therapy. J Drug Target 1998;5:163-169.
130. Chinnery PF, Taylor RW, Diekert K, Lill R, Turnbull DM, Lightowlers RN. Peptide nucleic acid delivery to human mitochondria. Gene Ther 1999;6:1919-1928.
131. Kotani H, Kmiec EB. A role for RNA synthesis in homologous pairing events. Mol Cell Biol 1994; 14:6097-6106.
132. Kotani H, Germann MW, Andrus A, Vinayak R, Mullah B, Kmiec EB. RNA facilitates Reck-mediated DNA pairing and strand transfer between molecules bearing limited regions of homology. Mol Gen Genet 1996;250:626-634.
133. Kren BT, Metz R, Kumar R, Steer CJ. Gene repair using chimeric RNA/DNA oligonucleotides. Semin Liver Dis 1999;19:93-104.
134. Yáñez, RJ, Porter ACG. Gene targeting is enhanced in human cells overexpressing hRAD51. Gene Ther 1999;6:1282-1290.
135. Modrich P. Strand-specific mismatch repair in mammalian cells. J Biol Chem 1997;272:24727-24730.
136. Yoon K, Cole-Strauss A, Kmiec EB. Targeted gene correction of episomal DNA in mammalian cells mediated by a chimeric RNA · DNA oligonucleotide. Proc Natl Acad Sci U S A 1996;93:2071-2076.
137. Cole-Strauss A, Yoon K, Xiang Y, Byrne BC, Rice MC, Gryn J, et al. Correction of the mutation responsible for sickle cell anemia by an RNA-DNA oligonucleotide. Science 1996;273:1386-1389.
138. Cole-Strauss A, Gamper H, Holloman WK, Muñoz M, Cheng N, Kmiec EB. Targeted gene repair directed by the chimeric RNA/DNA oligonucleotide in a mammalian cell-free extract. Nucleic Acids Res 1999;27:1323-1330.
139. Alexeev V, Yoon K. Stable and inheritable changes in genotype and phenotype of albino melanocytes induced by an RNA-DNA oligonucleotide. Nat Biotechnol 1998;16:1343-1346.
140. Santana E, Peritz AE, Iyer S, Uitto J, Yoon K. Different frequency of gene targeting events by the RNA-DNA oligonucleotide among epithelial cells. J Invest Dermatol 1998;111:1172-1177.
141. Kren BT, Cole-Strauss A, Kmiec EB, Steer CJ. Targeted nucleotide exchange in the alkaline phosphatase gene of HuH-7 cells mediated by a chimeric RNA/DNA oligonucleotide. Hepatology 1997;25:1462-1468.
142. Kren BT, Bandyopadhyay P, Steer CJ. In vivo site-directed mutagenesis of the factor IX gene by chimeric RNA/DNA oligonucleotides. Nat Med 1998;4:285-290.
143. Steer CJ, Kren BT, Chowdhury NR, Chowdhury JR. Liver-directed gene therapy. In: Arias IM, Boyer JL, Fausto N, Schachter D, Shafritz DA, eds. The Liver: Biology and Pathobiology. 4th ed. New York: Lippincott Williams & Wilkins; 2001: 941-962.
144. Kren BT, Parashar B, Bandyopadhyay P, Chowdhury NR, Chowdhury JR, Steer CJ. Correction of the UDP-glucuronosyltransferase gene defect in the Gunn rat model of Crigler-Najjar syndrome type I with a chimeric oligonucleotide. Proc Natl Acad Sci U S A 1999;96:10349-10354.
145. Tagalakis AD, Graham IR, Riddell DR, Dickson JG, Owen JS. Gene correction of the apolipoprotein (apo) E2 phenotype to wild-type apoE3 by in situ chimeraplasty. J Biol Chem 2001;276:13226-13230.
146. Rice MC, Bruner M, Czymmek K, Kmiec EB. In vitro and in vivo nucleotide exchange directed by chimeric RNA/DNA oligonucleotides in Saccharomyces cerevisae. Mol Microbiol 2001;40:857-868.
147. Alexeev V, Igoucheva O, Domashenko A, Cotsarelis G, Yoon K. Localized in vivo genotypic and phenotypic correction of the albino mutation in skin by RNA-DNA oligonucleotide. Nat Biotechnol 2000;18:43-47
148. Lai L-W, Chau B, Lien Y-HH. In vivo gene targeting in carbonic anhydrase II deficient mice by chimeric RNA/DNA oligonucleotides. Washington, DC, 2nd Annual Meeting of the American Society of Gene Therapy 1999;A236.
149. Lai L, Dory D, Khan R, Omera M, Lien Y-H. Conversion of a single base pair mutation in newborn carbonic anhydrase (CA) II deficient mice by chimeric RNA/DNA oligonucleotides. Mol Therapy 2001;3:S295.
150. Bartlett RJ, Stockinger S, Denis MM, Bartlett WT, Inverardi L, Le TT, et al. In vivo targeted repair of a point mutation in the canine dystrophin gene by a chimeric RNA/DNA oligonucleotide. Nat Biotechnol 2000;18:615-622.
151. Rando TA, Disatnik MH, Zhou LZ-H. Rescue of dystrophin expression in mdx mouse muscle by RNA/DNA oligonucleotides. Proc Natl Acad Sci U S A 2000;97:5363-5368.
152. Bertoni C, Rando T. Dystrophin gene repair in mdx muscle precursor cells in vitro and in vivo mediated by RNA-DNA chimeric oligonucleotides. Hum Gene Ther 2002;13:707-718.
153. Beetham PR, Kipp RB, Sawycky YL, Arntzen CJ, May GD. A tool for functional plant genomics: Chimeric RNA/DNA oligonucleotides cause in vivo gene-specific mutations. Proc Natl Acad Sci U S A 1999;96:8874-8778.
154. Rice MC, May GD, Kipp PB, Parekh H, Kmiec EB. Genetic repair of mutations in plant cell-free extracts directed by specific chimeric oligonucleotides. Plant Physiol 2000;123:427-438.
155. Zhu T, Peterson DJ, Tagliani L, St. Claire G, Baszczynski CL, Bowen B. Targeted manipulation of maize genes in vivo using chimeric RNA/DNA oligonucleotides. Proc Natl Acad Sci U S A 1999;96:8768-8773.
156. Gamper HB Jr, Cole-Strauss A, Metz R, Parekh H, Kumar R, Kmiec EB. A plausible mechanism for gene correction by chimeric oligonucleotides. Biochemistry 2000;39:5808-5816.
157. Gamper HB, Parekh H, Rice MC, Bruner M, Youkey H, Kmiec EB. The DNA strand of chimeric RNA/DNA oligonucleotides can direct gene repair/conversion activity in mammalian and plant cell-free extracts. Nucleic Acids Res 2000;28:4332-4339.
158. Igoucheva O, Alexeev V, Yoon K. Targeted gene correction by small single-stranded oligonucleotides in mammalian cells. Gene Ther 2001;8:391-399.
159. Chan PP, Glazer PM. Triplex DNA: Fundamentals, advances, and potential applications for gene therapy. J Mol Med 1997;75:267-282.
160. Luo Z, Macris MA, Faruqi AF, Glazer PM. High-frequency intrachromosomal gene conversion induced by triplex-forming oligonucleotides microinjected into mouse cells. Proc Natl Acad Sci U S A 2000;97:9003-9008.
161. Datta HJ, Chan PP, Vasquez KM, Gupta RC, Glazer PM. Triplex-induced recombination in human cell-free extracts. Dependence on XPA and HsRad51. J Biol Chem 2001;276:18018-18023.
162. Chan PP, Lin M, Faruqi AF, Powell J, Seidman MM, Glazer PM. Targeted correction of an episomal gene in mammalian cells by a short DNA fragment tethered to a triplex-forming oligonucleotide. J Biol Chem 1999;274:11541-11548.
163. Culver KW, Hsieh WT, Huyen Y, Chen V, Liu J, Khripine Y, et al. Correction of chromosomal point mutations in human cells with bifunctional oligonucleotides. Nat Biotechnol 1999;17:989-993.
164. Kunzelmann K, Legendre JY, Knoell DL, Escobar LC, Xu Z, Gruenert DC. Gene targeting of CFTR DNA in CF epithelial cells. Gene Ther 1996;3:859-867.
165. Goncz KK, Kunzelmann K, Xu Z, Gruenert DC. Targeted replacement of normal and mutant CFTR sequences in human airway epithelial cells using DNA fragments. Hum Mol Genet 1998;7:1913-1919.
166. Colosimo A, Goncz KK, Novelli G, Dallapiccola B, Gruenert DC. Targeted correction of a defective selectable marker gene in human epithelial cells by small DNA fragments. Mol Ther 2001;3:178-185.
167. Kapsa R, Quigley A, Lynch GS, Steeper K, Kornberg AJ, Gregorevic P, et al. In vivo and in vitro correction of the mdx dystrophin gene nonsense mutation by short-fragment homologous replacement. Hum Gene Ther 2001;12:629-642.
168. Goncz KK, Colosimo A, Dallapiccola. B, Gagné L, Hong K, Novelli G, et al. Expression of ΔF508 CFTR in normal mouse lung after site-specific modification of CFTR sequences by SFHR. Gene Ther 2001;8:961-965.
169. Inoue N, Dong R, Hirata RK, Russell DW. Introduction of single base substitutions at homologous chromosomal sequences by adeno-associated virus vectors. Mol Ther 2001;3:526-530.
170. Caplen NJ, Taylor JP, Statham VS, Tanaka F, Fire A, Morgan RA. Rescue of polyglutamine-mediated cytotoxicity by double-stranded RNA-mediated RNA interference. Hum Mol Genet 2002;11:175-184.
171. Yu J-Y, DeRuiter SL, Turner DL. RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells. Proc Natl Acad Sci U S A 2002;99:6047-6052.